Preparation of prostaglandin E1-hydroxypropyl-β- cyclodextrin complex and its nasal delivery in rats

International Journal of Pharmaceutics

Volumn 290, Issue 1-2, 2005, Pages 101-108

  Gu, Fu Gen ^a   Cui, Fu De ^a   Gao, Yong Liang ^b  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

Author keywords

Complex; HP CD; Nasal delivery; Prostaglandin E1; Solubility; Stability

Indexed keywords

PROSTAGLANDIN E1 DERIVATIVE; PROSTAGLANDIN E1 HYDROXYPROPYL BETA CYCLODEXTRIN; UNCLASSIFIED DRUG; BETA CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE; PROSTAGLANDIN E1;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CILIARY MOTILITY; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; INTERMETHOD COMPARISON; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; COMPARATIVE STUDY; INTRANASAL DRUG ADMINISTRATION; METHODOLOGY; SYNTHESIS; WISTAR RAT;

ADMINISTRATION, INTRANASAL; ALPROSTADIL; ANIMALS; BETA-CYCLODEXTRINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; MALE; RATS; RATS, WISTAR;

EID: 12344331527     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2004.11.021     Document Type: Article

References (29)

1. 1 in fatty alcohol propylene glycol ointment by acidic cyclodextrin derivative, O-carboxymethyl-O-ethyl-β-cyclodextrin Chem. Pharm. Bul1. 40 1992 1586 1591
2. C.R. Behl, H.K. Pimplaskar, A.P. Sileno, J. Demeireles, and V.D. Romeo Effects of physicochemical properties and other factors on systemic nasal drug delivery Adv. Drug. Del. Rev. 29 1998 89 116
3. T.O. Carpenter, A. Gerloczy, and J. Pitha Safety of parenteral hydroxypropyl β-cyclodextrin J. Pharm. Sci. 84 1995 222 225
4. 1) in healthy volunteers following intravenous infusion Br. J. Clin. Pharmacol. 40 1995 273 276
5. G. Dollo, P.L. Corre, M. Chollet, F. Chevanne, M. Bertault, J.L. Burgot, and R.L. Verge Improvement in solubility and dissolution rate of 1, 2-dithiole-3-thiones upon complexation with β-cyclodextrin and its hydroxypropyl and sulfobutyl ether-7 derivatives J. Pharm. Sci. 88 1999 889 895
6. 1: in vitro and laser doppler flowmetry study J. Pharm. Sci. 87 1998 721 725
7. 1) in physiological solutions by liquid chromatography (HPLC) Int. J. Pharm. 115 1995 113 117
8. 1 J. Chin. Pharm. Sci. 13 2004 158 165
9. W.A.J.J. Hermens, and F.W.H.M. Merkus The influence of drugs on nasal ciliary movement Pharm. Res. 4 1987 445 449
10. W.A.J.J. Hermens, M.J.M. Deurloo, S.G. Romeyn, J.C. Verhoef, and F.W.H.M. Merkus Nasal absorption enhancement of 17β-estradiol by dimethyl-β-cyclodextrin in rabbits and rats Pharm. Res. 7 1990 500 503
11. T. Higuchi, and K.A. Connors Phase solubility techniques Adv. Anal. Chem. Instrum. 4 1965 117 212
12. 1 (lipo-AS013) due to vascular wall targeting J. Control Release 71 2001 157 164
13. X.G. Jiang, J.B. Cui, X.L. Fang, Y. Wei, and N.Z. Xi Toxicity of drugs on nasal mucocilia and the method of its evaluation Acta Pharm. Sin. 30 1995 848 853
14. E. Marttin, S.G. Romeijn, and J.C. Verhoef Nasal absorption of dihydroergotamine from liquid and powder formulations in rabbits J. Pharm. Sci. 86 1997 802 807
15. F.W.H.M. Merkus, J.C. Verhoef, S.G. Romeijn, and N.G.M. Schipper Absorption enhancing effect of cyclodextrins on intranasally administered insulin in rats Pharm. Res. 8 1991 588 591
16. 1 is more effective, when incorporated in lipid microspheres, for treatment of peripheral vascular diseases in man J. Pharm. Pharmacol. 35 1983 666 667
17. 2 J. Pharm. Sci. 62 1973 576 580
18. K. Moromoto, H. Yamaguchi, Y. Iwakura, M. Miyazaki, E. Nakatani, T. Iwamoto, Y. Ohashi, and Y. Nakai Effects of proteolytic enzyme inhibitors on the nasal absorption of vasopressin and an analogue Pharm. Res. 8 1991 1175 1179
19. E. Puchelle, and J.M. Tournier The frog palate for studying mucus transport velocity and mucociliary frequency J. Respir. Dis. 64 1983 293 296
20. N.G.M. Schipper, W.A.J.J. Hermens, S.G. Romeyn, J. Verhoef, and F.W.H.M. Merkus Nasal absorption of 17-beta-estradiol and progesterone from a dimethyl-cyclodextrin inclusion formulation in rats Int. J. Pharm. 64 1990 61 66
21. H. Schweer, J. Kammer, and H.W. Seyberth Simultaneous determination of prostanoids in plasma by gas chromatography-negative-ion chemical-ionization mass spectrometry J. Chromatogr. 338 1985 273 280
22. 0 by gas chromatography/negative ion chemical ionization triple stage quadrupole mass spectrometry Bio. Mass. Spectrom. 23 1994 221 227
23. 1 versus pentoxifylline therapy in chronic arterial occlusive disease - a controlled randomized multicenter study VASA 28 1989 44 49
24. 1 by γ-cyclodextrin complexation Chem. Pharm. Bull. 32 1984 275 279
25. 1 on penile erection and erectile failure J. Urol. 137 1987 1010
26. J.L. Wallace Prostaglandins, NSAIDS and Cytoprotection Gastroenterrol. Clin. North Am. 21 1992 631 634
27. 1 Tianjin. Pharm. 14 2002 20 21
28. 1 with α-cyclodextrin in aqueous systems: Stability of the inclusion complex J. Pharm. Sci. 80 1991 153 156
29. 1 by maltosyl-β-cyclodextrin in lyophilized formulation Chem. Pharm. Bull. 40 1992 747 751